Intermittent Corticosteroid Maintenance Treatment of Psoriasis: A Double-Blind Multicenter Trial of Augmented Betamethasone Dipropionate Ointment in a Pulse Dose Treatment Regimen

Katz, Harry Irving; Prawer, Steven E.; Medansky, Roland S.; Krueger, Gerald G.; Mooney, John J.; Jones, Mitchell L.; Samson, Cesar R.

doi:10.1159/000247698

Cited by 70 publications

(65 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most relapses have been reported to occur within the first month after discontinuation of a topical steroid [20], so an 8-week observation period in this study should have been long enough to detect most relapses. Exacerbation of inflammatory illness following discontinuation of corticosteroid treatment is one of the main disadvantages of corticosteroid use.…”

Section: Discussionmentioning

confidence: 99%

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

et al. 2011

View full text Add to dashboard Cite

Objective: To establish the efficacy and safety of once daily treatment of Daivobet®/Dovobet® gel in patients with psoriasis vulgaris, relative to tacalcitol ointment and the gel vehicle alone. Methods: 458 patients with at least moderately severe disease were randomized in 3 treatment arms for an 8-week period. Treatment was investigator blinded, and treatment success was defined as patients with an Investigator’s Global Assessment of ‘clear’ or ‘almost clear’ at week 8. Results: The proportion of patients who were ‘clear or almost clear’ was significantly higher in the 2-compound gel group (39.9%) compared with 17.9% in the tacalcitol group and 5.5% in the gel vehicle group: p < 0.001 in both comparisons. The proportion of patients with at least 1 adverse drug reaction was significantly lower in the 2-compound gel group compared to the other 2 treatment groups. Conclusions: Once-a-day treatment with the 2-compound Daivobet/Dovobet gel is a safe and efficacious therapeutic regimen for individuals with psoriasis on the body.

show abstract

Section: Discussionmentioning

confidence: 99%

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

et al. 2011

View full text Add to dashboard Cite

show abstract

“…There is a perception of tachyphylaxis with long-term corticosteroid use [13]. However, studies have shown that intermittent use of topical corticosteroids kept psoriasis in remission for 4 months in 75% of patients [14], was clinically beneficial for up to 6 months [15], and was an efficacious maintenance therapy when used for 12 weeks [16]. A study investigating the clinical incidence of corticosteroid tachyphylaxis found no evidence of it after 12 weeks of continuous corticosteroid use [17].…”

Section: Discussionmentioning

confidence: 99%

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

et al. 2006

View full text Add to dashboard Cite

Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol.

show abstract

“…The most fre of an intermittent maintenance therapy depends on the ac tivity of the disease on the one hand and on the potency of CS on the other: treatment-free intervals mostly last for 3-12 days. It could be demonstrated that superpotent CS (compared to poor acting) causes rare and late recurrences [3,4]. Presumably, the skin thinning caused by the continu ous application in the first step completely resolves during the intermittent application in the second (maintenance) step.…”

Section: Introductionmentioning

confidence: 99%

“…Especially in psoriatic diseases and chronic hand ecze ma a long-lasting intermittent maintenance therapy was tested clinically [2][3][4][5], Katz et al [4] termed the CS appli cation every 7th day as weekend therapy.…”

mentioning

confidence: 99%

Skin Atrophy Induced by Initial Continuous Topical Application of Clobetasol Followed by Intermittent Application

Lubach¹,

Rath²,

Kietzmann

1995

Dermatology

View full text Add to dashboard Cite

Background: The most frequent side effect of a long-term topical corticosteroid therapy is skin atrophy. To avoid or to reduce atrophy often an initial continuous application is followed by an intermittent maintenance therapy. Objective: In this study we measured the skin thickness before and after the two-phase application schedule with the superpotent topical steroid clobetasol propionate (CP). For 16 days CP samples were applied twice daily on the test areas of 12 volunteers (phase 1). Then CP was applied to the same skin areas in accordance with the following timing: every 5th day, every 7th day, every 10th day, every 14th day (phase 2). Phase 2 lasted for 45 days. During the entire period of the study the skin thickness was measured regularly by the skin compression and thickness method as described previously. Results: It could be seen that in phase 1 the skin became about 15% thinner. In phase 2 the steroid-induced skin thinning was approximately the same when CP was applied every 5th or 7th day. The skin thickness reached a more or less normal level when CP was applied every 10th day. After the 14th day a completely normal level was found. By measuring the skin thickness every day it was further shown that the skin thinning process lasted for 3 days when CP was applied once only. Conclusion: These results demonstrate that skin thinning must be expected by an intermittent maintenance therapy applied at relatively short intervals. The longer the intervals, the weaker the skin thinning. Moreover, these investigations showed that the skin thinning effect after a single CP application persists for nearly 3 days.

show abstract

Intermittent Corticosteroid Maintenance Treatment of Psoriasis: A Double-Blind Multicenter Trial of Augmented Betamethasone Dipropionate Ointment in a Pulse Dose Treatment Regimen

Cited by 70 publications

References 6 publications

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

Skin Atrophy Induced by Initial Continuous Topical Application of Clobetasol Followed by Intermittent Application

Contact Info

Product

Resources

About